Diligence memo · auto-generated · as of July 2, 2026

Locus Solutions, LLC/OH

Locus Solutions, LLC/OH looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Locus Solutions, LLC/OH operates in Biotechnology, based in SOLON.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Locus Solutions, LLC/OH has raised $25M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $20M on 2019-11-21.

Most recent recorded round closed around 2022-05-09.

Valuation (modeled)modeled

Provath models Locus Solutions, LLC/OH at approximately $85M (range $9.5M–$229M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.51× the median modeled value of Series B Biotechnology companies in 2022–2024 (197 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 30 months.

Last raise 4.1 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 4.3× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 72% of Biotechnology peers (4293 compared).

Modeled value ranks above 55% of those peers.

Closest niche peers: Mt McKinley Medical Holding Corp USA, YAP Therapeutics Inc, Pinteon Therapeutics, Inc., OncXerna Therapeutics, Ltd., EpiBiologics, Inc..

Peoplefiled

11 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.